Ferric maltol: new iron therapy for patients with inflammatory bowel disease

Feraccru (ferric maltol) is licensed for the treatment of iron-deficiency anaemia in patients with inflammatory bowel disease (IBD).

 The intestinal mucosa in patients with ulcerative colitis and Crohn's disease is particularly sensitive to iron ingestion. | SCIENCE PHOTO LIBRARY
The intestinal mucosa in patients with ulcerative colitis and Crohn's disease is particularly sensitive to iron ingestion. | SCIENCE PHOTO LIBRARY

Further information
View Feraccru drug record
Summary of Product Characteristics
Manufacturer: Shield Therapeutics
MIMS Gastroenterology Clinic

Conventional oral iron supplements tend to worsen gastrointestinal symptoms in patients with inflammatory bowel disease. Feraccru, a new oral iron product with an improved gastrointestinal tolerability profile, may be useful as an alternative to intravenous iron in these patients. 

The iron in Feraccru is in a stable state as a complex with a ligand. The complex provides controlled release of iron for uptake across the intestinal wall and transfer to the iron transport and storage proteins (transferrin and ferritin). On uptake from the gastrointestinal tract, the complex dissociates, leaving the iron alone to enter the systemic circulation.

Feraccru is given at a dose of one capsule twice daily, taken on an empty stomach. Treatment is normally continued for at least 12 weeks depending on severity.

No impact on bowel disease

The safety and tolerability of ferric maltol were assessed in a randomised, double-blind, placebo-controlled trial involving 128 patients with ulcerative colitis or Crohn's disease (quiescent or mild to moderate) who had previously failed treatment with oral iron. Patients were randomised to receive either ferric maltol or placebo twice daily for 12 weeks.

At week 12, patients in the ferric maltol group showed a significant increase in haemoglobin concentration compared with those in the placebo group (mean 2.25g/dL, p<0.0001)

Ferric maltol had no impact on the severity of inflammatory bowel disease, with a safety profile comparable to placebo. The most frequent adverse effects in both groups were abdominal pain, diarrhoea and constipation.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases